Open access
Open access
Powered by Google Translator Translator

Oncology (all articles)

Cohort Study | Association of Taxane type with chemotherapy-induced peripheral neuropathy in patients with breast cancer.

4 Nov, 2022 | 13:15h | UTC

Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer – JAMA Network Open 

 

M-A | Risk of major adverse events associated with gabapentinoid and opioid combination therapy.

4 Nov, 2022 | 13:13h | UTC

Risk of major adverse events associated with gabapentinoid and opioid combination therapy: A systematic review and meta-analysis – Frontiers in Pharmacology

 

ASCO Policy Statement | Electronic nicotine delivery systems.

3 Nov, 2022 | 14:03h | UTC

Electronic Nicotine Delivery Systems: An Updated Policy Statement From the American Association for Cancer Research and the American Society of Clinical Oncology – Journal of Clinical Oncology

Commentary: Updated policy regarding electronic nicotine delivery systems – Yale Cancer Center

 

Cohort Study | Mental health morbidities and time to cancer diagnosis among adults with colon cancer in England.

3 Nov, 2022 | 13:55h | UTC

Mental Health Morbidities and Time to Cancer Diagnosis Among Adults With Colon Cancer in England – JAMA Network Open 

Invited Commentary: The Interface Between Colon Cancer and Mental Health Morbidities – JAMA Network Open

 

Cohort Study | Association of sinoatrial node radiation dose with atrial fibrillation and mortality in patients with lung cancer.

3 Nov, 2022 | 13:39h | UTC

Association of Sinoatrial Node Radiation Dose With Atrial Fibrillation and Mortality in Patients With Lung Cancer – JAMA Oncology (link to abstract – $ for full-text)

Commentaries:

Sinoatrial Node Radiation During CRT May Increase Risk of Atrial Fibrillation in SCLC and NSCLC – Cancer Network

Incidental sinoatrial node irradiation may increase AF risk in lung cancer – medwire News

 

Commentary on Twitter

 

Opinion | Should disease-free survival be used as a regulatory or clinical end point for adjuvant therapy of cancer?

3 Nov, 2022 | 13:37h | UTC

You’re Cured Till You’re Not: Should Disease-Free Survival Be Used as a Regulatory or Clinical End Point for Adjuvant Therapy of Cancer? – Journal of Clinical Oncology

 

NICE Guideline Update | Lung cancer: diagnosis and management.

2 Nov, 2022 | 14:28h | UTC

Lung cancer: diagnosis and management – National Institute for Health and Care Excellence

 

Single-arm P2 study | Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy.

2 Nov, 2022 | 14:23h | UTC

Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)

News Release: Some breast cancer patients with high responses to chemotherapy may not need surgery: Biopsy protocol identifies patients at low risk of recurrence – University of Texas M. D. Anderson Cancer Center

Commentary: Elimination of Surgery Explored for Selected Breast Cancer Patients – HealthDay

 

Commentary on Twitter

 

Study | The future risk of cervical precancer among HPV–negative women is increased with a history of HPV–positive results.

1 Nov, 2022 | 12:13h | UTC

Risk of cervical precancer among HPV–negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study – PLOS Medicine

 

RCT | Dabrafenib and Trametinib vs. Nivolumab and Ipilimumab for patients with advanced BRAF-mutant melanoma.

1 Nov, 2022 | 12:06h | UTC

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134 – Journal of Clinical Oncology

News Release: Advanced melanoma survival improves significantly when immunotherapy is given before targeted therapy – Georgetown University Medical Center

Commentary: Treatment Sequence Studied for Advanced BRAF-Mutant Melanoma – HealthDay

 

RCT | Photodynamic vs. white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer.

31 Oct, 2022 | 13:51h | UTC

Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT – Health Technology Assessment

 

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

31 Oct, 2022 | 13:51h | UTC

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up – Annals of Oncology

Related Guideline: ASCO Guideline | Treatment of metastatic colorectal cancer.

 

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.

31 Oct, 2022 | 13:50h | UTC

Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline – Annals of Oncology

 

Cohort Study | Risk factors of pancreatic cancer in patients with Type 2 DM.

31 Oct, 2022 | 13:47h | UTC

Risk Factors of Pancreatic Cancer in Patients With Type 2 Diabetes Mellitus: The Hong Kong Diabetes Study – Journal of the Endocrine Society

 

Study | No benefit from frailty screening over a geriatric-assessment-for-all approach in older patients with cancer.

31 Oct, 2022 | 13:40h | UTC

A Two-Step Frailty Assessment Strategy in Older Patients With Solid Tumors: A Decision Curve Analysis – Journal of Clinical Oncology

 

Nonsurgical options for risk reduction of contralateral breast cancer in BRCA mutation carriers with early breast cancer.

31 Oct, 2022 | 13:41h | UTC

Nonsurgical Options for Risk Reduction of Contralateral Breast Cancer in BRCA Mutation Carriers With Early-Stage Breast Cancer – Journal of Clinical Oncology (free for a limited period)

 

Post-trial follow-up | Pembrolizumab vs. chemotherapy as first-line therapy in PD-L1-expressing non–small-cell lung cancer.

31 Oct, 2022 | 13:39h | UTC

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study – Journal of Clinical Oncology

Original Study: Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial – The Lancet

 

Case Report | Acquired Hemophilia A secondary to an immune checkpoint inhibitor.

31 Oct, 2022 | 13:34h | UTC

Acquired Hemophilia A Secondary to an Immune Checkpoint Inhibitor: A Case Report – JTO Clinical and Research Reports

Commentary: Report Details Rare Case of Acquired Hemophilia A Secondary to Immune Checkpoint Inhibition

 

Cohort Study | Diverticular disease linked to increased risk of cancer outside the GI tract.

31 Oct, 2022 | 13:33h | UTC

Cancer risk in patients with diverticular disease: a nationwide cohort study – JNCI: Journal of the National Cancer Institute (link to abstract – $ for full-text)

News Release: Diverticular disease associated with cancer outside gastrointestinal tract – Karolinska Institutet

 

2022 ETA Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma.

27 Oct, 2022 | 12:33h | UTC

2022 ETA Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma – European Thyroid Journal

Commentary: New EU Guidelines: Individualize Care for Thyroid Cancer in Kids – Medscape (free registration required)

 

[News Release] RCT | Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer.

27 Oct, 2022 | 12:32h | UTC

News Release: Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer – ASTRO Annual Meeting

Abstract: Conventional vs. Hypofractionated, Radiotherapy for High-Risk Prostate Cancer: 7-Year Outcomes of the Randomized, Non-Inferiority, Phase 3 PCS5 Trial – ASTRO Annual Meeting

 

RCT | Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel.

27 Oct, 2022 | 12:23h | UTC

Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: PRESIDE Trial Meets Primary End Point With Continuous Enzalutamide After Progression of mCRPC – Cancer Network

 

Expert Consensus | Imaging standardization in metastatic colorectal cancer.

26 Oct, 2022 | 14:36h | UTC

Imaging standardisation in metastatic colorectal cancer: A joint EORTC-ESOI-ESGAR expert consensus recommendation – European Journal of Cancer

 

The bleeding cervical cancer patient: systematic approach and management.

26 Oct, 2022 | 14:30h | UTC

The Bleeding Cervical Cancer Patient: Systematic Approach and Management – emDocs

 

Single-arm P2 study | Toxic effects of stereotactic ablative radiotherapy for up to 5 oligometastases in patients with cancer.

26 Oct, 2022 | 14:28h | UTC

Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

Commentary: Stereotactic Ablative Body Radiotherapy Produces Acceptable Toxic Effects in Patients With Cancer and Oligometastses – Cancer Network

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.